A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects with Type 2 Diabetes
Study identifier:137-156
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects with Type 2 Diabetes Who Are Not Achieving Glycemic Targets
Medical condition
Type 2 Diabetes Mellitus
Phase
Phase 4
Healthy volunteers
No
Study drug
pramlintide acetate
Sex
All
Actual Enrollment
200
Study type
Interventional
Age
18 Years - 75 Years
Date
Study Start Date: 01 Oct 2005
Primary Completion Date: 01 Jun 2006
Study Completion Date: 01 Jun 2006
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Mar 2015 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
N/A
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Pramlintide | Drug: pramlintide acetate Clear, colorless, sterile solution for SC injection |
Contacts
Investigators
Principal Investigator
Lisa Porter
Amylin Pharmaceuticals
